Nurix Therapeutics, Inc. (NRIX) Earnings History
Annual and quarterly earnings data from 2018 to 2025
Loading earnings history...
NRIX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
NRIX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 77.5% | -340.2% | -314.9% |
| 2024 | -306.3% | -390.5% | -354.9% |
| 2023 | -145.7% | -201.4% | -187.0% |
| 2022 | -377.6% | -476.0% | -466.9% |
| 2021 | -291.4% | -396.3% | -393.9% |
Download Data
Export NRIX earnings history in CSV or JSON format
Free sign-in required to download data
Nurix Therapeutics, Inc. (NRIX) Earnings Overview
As of May 8, 2026, Nurix Therapeutics, Inc. (NRIX) reported trailing twelve-month net income of -$264M, reflecting -5.9% year-over-year growth. The company earned $-2.78 per diluted share over the past four quarters, with a net profit margin of -314.9%.
Looking at the long-term picture, NRIX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$9M in fiscal 2018.
Nurix Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ARVN (-$81M net income, -30.8% margin), KYMR (-$315M net income, -794.4% margin), PRAX (-$327M net income), NRIX has room to improve margins relative to the peer group. Compare NRIX vs ARVN →
NRIX Earnings vs Peers
Earnings metrics vs comparable public companies
NRIX Historical Earnings Data (2018–2025)
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$264M | -36.6% | -$286M | $-3.05 | -314.9% | -340.2% |
| 2024 | -$194M | -34.5% | -$213M | $-2.88 | -354.9% | -390.5% |
| 2023 | -$144M | +20.2% | -$155M | $-2.65 | -187.0% | -201.4% |
| 2022 | -$180M | -53.9% | -$184M | $-3.71 | -466.9% | -476.0% |
| 2021 | -$117M | -171.0% | -$118M | $-2.73 | -393.9% | -396.3% |
| 2020 | -$43M | -99.3% | -$65M | $-2.76 | -242.7% | -364.7% |
| 2019 | -$22M | -130.2% | -$22M | $-0.56 | -69.7% | -71.5% |
| 2018 | -$9M | - | -$10M | $-0.59 | -25.2% | -26.0% |
See NRIX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NRIX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NRIX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonNRIX — Frequently Asked Questions
Quick answers to the most common questions about buying NRIX stock.
Is NRIX growing earnings?
NRIX EPS fell to $-2.78, with earnings declining -5.9%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-264M.
What are NRIX's profit margins?
Nurix Therapeutics, Inc. net margin is -314.9%, with operating margin at -340.2%. Below-average margins reflect competitive or cost pressures.
How consistent are NRIX's earnings?
NRIX earnings data spans 2018-2025. The declining earnings trend is -5.9% YoY. Historical data enables comparison across business cycles.